Keep your SARS-CoV-2 testing workflows running at full speed
Reagents for testing and public health labs
One of the many challenges of the public health response to COVID-19 is ensuring that labs have enough high-quality reagents for uninterrupted SARS-CoV-2 testing. With our immense oligonucleotide synthesis capacity and robust reagent supply chain, LGC, Biosearch Technologies™ can remove reagent bottlenecks and keep your SARS-CoV-2 testing workflows running at full speed.
Secure your supply chain needs for scalable SARS-CoV-2 detection
We have mobilised all necessary resources to support global testing requirements. From nucleic acid extraction and purification to critical assay components such as enzymes, master mix, probes and primers, we enable you to respond to COVID-19 rapidly and at scale.
Why choose Biosearch Technologies to support your COVID-19 detection programs?
Easily order probes and primers by protocol, including a CDC-qualified probe and primer kit
Run your tests with the confidence of knowing that the powerful BHQ™ and BBQ-650™ dyes used in many of the SARS-CoV-2 protocols are coming straight from the company that is the original supplier and inventor
Leverage sensitive and robust qPCR enzymes and master mixes from the trusted partner of the world’s top 10 molecular diagnostic firms
All COVID-19 orders will be prioritised and expedited for detection at scale
“Biosearch Beats the Deadline - Yet another partner went above and beyond: Biosearch Technologies in Novato, in Northern California, produces the Black Hole Quencher dye label used for probe technology in both the five target and H1N1 assays. It increased production at the onset of the pandemic to meet US and international demand for test reagents.”
Excerpt from page 80 of “Lessons from a virus: Public Health Laboratories Respond to the H1N1 Pandemic” Association for Public Health Laboratories
The Biosearch Blog
Get more in-depth insights about COVID-19 and how LGC, Biosearch Technologies is supporting the rapid response to the pandemic from our blog.
Recorded Q&A panel discussion: How to establish COVID-19 diagnostics and keep up with demand
Three leading experts discuss the experiences and challenges they faced when developing, validating and going live with a SARS CoV-2 assay in routine diagnostics as well as the challenges of ramping up test volumes to meet demand while maintaining quality standards. In addition, products specifically designed for SARS-CoV-2 testing, assay validation and QC that can support continued diagnostics at high volumes will be discussed by LGC experts.
LGC SeraCare offer a complete Quality Solution for COVID-19 diagnostic assay validation
AccuPlex™ technology mimics wild-type pathogenic viruses, but is safe, non-infectious, and replication deficient. These materials serve as true, full-process quality solutions that challenge the entire diagnostic workflow, making them the preferred alternative to infectious materials.
Together, the AccuPlex SARS-CoV-2 Verification Panel and AccuPlex SARS-CoV-2 Reference Material Kit offer an ideal solution for clinical laboratories looking for a safe, effective tool to verify and monitor SARS-CoV-2 molecular assay performance. Products contain positive materials directed against the published CDC and WHO consensus sequences and the S gene. Negative materials targeting the human RNase P gene are also included.
“We just went ‘live’ with the SARS-CoV-2 assay…I’ve never brought in and validated an assay in 7 days. The LGC SeraCare reference material works perfectly. I needed something other than the assay’s positive control to create a positive assay result before I felt comfortable releasing the assay for patient testing, and your product did the trick.”
Medical Director, Clinical Chemistry Laboratory prominent Boston Academic Medical Hospital
Confidently meet surging demand with a large-scale, end-to-end testing solution.
As the need for SARS-CoV-2 testing continues to grow for both diagnostic and screening applications, many organizations are looking to expand or create testing capacity. For existing diagnostic labs, limited supplies of instruments, reagents and laboratory technologists make getting high volumes of testing done in a timely manner challenging.
Biosearch Technologies offers fully automated PCR testing technology that is redefining high-throughput for SARS-CoV-2 detection to 35,000 tests per day on a single system. To further enable mass testing, our ultra-high-throughput PCR testing system is capable of processing up to 150,000 tests per day on a single system.